• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

切除术后胰腺导管腺癌患者的复发模式及其危险因素:272 例回顾性分析。

Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients.

机构信息

Department of General and Visceral Surgery, Friedrich-Alexander-University, Krankenhausstraße 12, Erlangen, Germany.

Department of General and Visceral Surgery, Friedrich-Alexander-University, Krankenhausstraße 12, Erlangen, Germany.

出版信息

Pancreatology. 2024 Sep;24(6):930-937. doi: 10.1016/j.pan.2024.07.017. Epub 2024 Aug 2.

DOI:10.1016/j.pan.2024.07.017
PMID:39103253
Abstract

BACKGROUND

The aim of this study was to investigate the patterns of recurrence and their associated risk factors in patients who underwent resection for pancreatic carcinoma.

METHODS

This retrospective study included 272 patients, who underwent Ro/R1-resection of PDAC from 2005 to 2020 at the University Hospital Erlangen. Risk factors for different recurrence patterns and the prognostic value of recurrence pattern on the overall survival after recurrence were evaluated.

RESULTS

61 % of the patients experienced recurrence, mostly within the first 12 postoperative months (62 %) and in the form of metastases (87 %). The median overall survival from recurrence was 9.2 months. The preoperative absence of diabetes and the presence of lymph node metastasis were independent risk factors for recurrence and a preoperative CA19-9 exceeding 97 U/ml for early recurrence. Additionally, lymph node metastases were associated with a higher risk of metastatic recurrence. Early recurrence, but not the site of recurrence, was identified as an independent prognostic factor for worse overall survival from recurrence.

CONCLUSION

The occurrence of recurrence and especially of early and metastatic recurrence are associated with a worse overall survival. Patients lacking preoperative diabetes, having high preoperative CA19-9 values and lymph node metastases are particularly at risk for (early) recurrence.

摘要

背景

本研究旨在探讨接受胰腺癌切除术患者的复发模式及其相关的危险因素。

方法

本回顾性研究纳入了 2005 年至 2020 年期间在埃尔兰根大学医院接受 Ro/R1 切除术的 272 例 PDAC 患者。评估了不同复发模式的危险因素,以及复发模式对复发后总生存的预后价值。

结果

61%的患者出现复发,大多发生在术后 12 个月内(62%),且以转移的形式出现(87%)。复发后的中位总生存时间为 9.2 个月。术前无糖尿病和存在淋巴结转移是复发的独立危险因素,术前 CA19-9 超过 97 U/ml 与早期复发相关。此外,淋巴结转移与更高的转移性复发风险相关。早期复发而非复发部位被确定为复发后总生存的独立预后因素。

结论

复发的发生,尤其是早期和转移性复发与更差的总生存相关。术前无糖尿病、术前 CA19-9 水平较高和淋巴结转移的患者复发风险尤其高。

相似文献

1
Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients.切除术后胰腺导管腺癌患者的复发模式及其危险因素:272 例回顾性分析。
Pancreatology. 2024 Sep;24(6):930-937. doi: 10.1016/j.pan.2024.07.017. Epub 2024 Aug 2.
2
Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.可切除性胰腺导管腺癌患者术前预后因素的评估
Scand J Gastroenterol. 2019 Jun;54(6):780-786. doi: 10.1080/00365521.2019.1624816. Epub 2019 Jun 10.
3
Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?胰腺导管腺癌切除术后CA19-9恢复正常并不等同于治愈?
Asian Pac J Cancer Prev. 2015;16(2):661-6. doi: 10.7314/apjcp.2015.16.2.661.
4
Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.术后血清癌胚抗原(CEA)和糖类抗原125(CA125)水平在预测胰腺导管腺癌手术结果方面对围手术期糖类抗原19-9(CA19-9)水平具有补充作用。
Surgery. 2017 Feb;161(2):373-384. doi: 10.1016/j.surg.2016.08.005. Epub 2016 Nov 9.
5
Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.胰腺导管腺癌切除术后早期复发的预测
PLoS One. 2021 Apr 12;16(4):e0249885. doi: 10.1371/journal.pone.0249885. eCollection 2021.
6
Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.胰腺导管腺癌多学科治疗时代实际长期生存的预后因素。
Langenbecks Arch Surg. 2018 Sep;403(6):693-700. doi: 10.1007/s00423-018-1709-7. Epub 2018 Sep 15.
7
Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.根治性手术切除后可切除性胰腺导管腺癌患者早期复发的术前危险因素。
Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7.
8
Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.评估可切除的浸润性导管内乳头状黏液性癌患者的术前预后因素。
Surgery. 2020 Dec;168(6):994-1002. doi: 10.1016/j.surg.2020.01.014. Epub 2020 Mar 3.
9
Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.胰腺癌患者术前和术后CA19-9、SPan-1及DUPAN-II水平对预后影响的比较
Pancreatology. 2017 Jan-Feb;17(1):95-102. doi: 10.1016/j.pan.2016.10.004. Epub 2016 Oct 11.
10
Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.胰腺导管内乳头状黏液性恶性肿瘤手术切除后的预后。与胰腺导管腺癌的比较。
Gut. 2002 Nov;51(5):717-22. doi: 10.1136/gut.51.5.717.

引用本文的文献

1
Response and Resistance to RAS Inhibition in Cancer.癌症中对RAS抑制的反应与抗性
Cancer Discov. 2025 Jul 3;15(7):1325-1349. doi: 10.1158/2159-8290.CD-25-0349.
2
Perioperative Radiation for Patients with Resectable Pancreatic Cancer: an Updated Review After the Initial RTOG 0848 Results.可切除胰腺癌患者的围手术期放疗:基于RTOG 0848初始结果的最新综述
J Gastrointest Cancer. 2025 Feb 22;56(1):70. doi: 10.1007/s12029-025-01185-0.
3
Understanding the risk of recurrence after resection of intraductal papillary mucinous neoplasm-associated adenocarcinoma: insights from a large multicenter study.
了解导管内乳头状黏液性肿瘤相关腺癌切除术后的复发风险:来自一项大型多中心研究的见解。
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1041-1044. doi: 10.21037/hbsn-24-583. Epub 2024 Nov 8.